Atlas Trials

A Single Center Study of Donafenib Combined With PD-1 + TACE in the First-line Treatment of aHCC

Clinical trial NCT05262959 · COMPLETED

Trial details

NCT number
NCT05262959
Sponsor
Shanghai Zhongshan Hospital
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Donafenib
Start date
2021-12-01
Primary completion
2024-04-30
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.